Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Craig

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|February 23, 2020
A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous LeukemiaBenjamin K Tomlinson, Molly M Gallogly, Donna M Kane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2013
Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host diseaseMehdi Hamadani, Laura F Gibson, Scot C Remick, et al.
Leukemia Research Reports|July 29, 2014
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromesStuart L Goldberg, Pierre Fenaux, Michael D Craig, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 8, 2018
Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell TransplantationNarendranath Epperla, Mehdi Hamadani, Kwang W Ahn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 28, 2016
Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin LymphomaBinod Dhakal, Lauren Westfall Veltri, Timothy S Fenske, et al.
Cancers|February 11, 2023
Chemotherapeutic Activity of Pitavastatin in Vincristine Resistant B-Cell Acute Lymphoblastic LeukemiaDebbie Piktel, Javohn C Moore, Sloan Nesbit, et al.
Ecological Applications : a Publication of the Ecological Society of America|September 5, 2019
Fire-mediated habitat change regulates woodland bird species and functional group occurrenceCarl R Gosper, Simon J Watson, Elizabeth Fox, et al.
Haematologica|June 30, 2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myelomaJesús F San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Haematologica|May 26, 2018
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemiaFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Clinical Lymphoma, Myeloma & Leukemia|February 23, 2020
A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous LeukemiaBenjamin K Tomlinson, Molly M Gallogly, Donna M Kane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2013
Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host diseaseMehdi Hamadani, Laura F Gibson, Scot C Remick, et al.
Leukemia Research Reports|July 29, 2014
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromesStuart L Goldberg, Pierre Fenaux, Michael D Craig, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 8, 2018
Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell TransplantationNarendranath Epperla, Mehdi Hamadani, Kwang W Ahn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 28, 2016
Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin LymphomaBinod Dhakal, Lauren Westfall Veltri, Timothy S Fenske, et al.
Cancers|February 11, 2023
Chemotherapeutic Activity of Pitavastatin in Vincristine Resistant B-Cell Acute Lymphoblastic LeukemiaDebbie Piktel, Javohn C Moore, Sloan Nesbit, et al.
Ecological Applications : a Publication of the Ecological Society of America|September 5, 2019
Fire-mediated habitat change regulates woodland bird species and functional group occurrenceCarl R Gosper, Simon J Watson, Elizabeth Fox, et al.
Haematologica|June 30, 2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myelomaJesús F San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Haematologica|May 26, 2018
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemiaFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Pageof 4